Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

Phase 1/2 clinical trial is to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IDP-121 combined with chemotherapy in patients with advanced unresectable/metastatic SCLC that have progressed after 1st line platinum- based chemotherapy, considering the role of MYC amplification in the development of platinum resistance.

Trial Details

NCT ID
NCT07864207
Phase
PHASE1 / PHASE2
Sponsor
IDP Discovery Pharma S.L.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • IDP-121
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899
  • Las Palmas de Gran Canaria, Spain|28.10178,-15.41573
  • Madrid, Spain|40.4165,-3.70256
  • Málaga, Spain|36.72016,-4.42034

Key Eligibility Criteria

  • Age ≥18 years
  • Performance status (ECOG) ≤ 2
  • Life expectancy ≥2 months
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →